cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Exelixis Inc
19 own
35 watching
Current Price
$22.56
$0.32
(1.44%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
7,668.31M
52-Week High
52-Week High
24.34000
52-Week Low
52-Week Low
16.15000
Average Volume
Average Volume
2.92M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
37.9484
iconMarket Capitalization7,668.31M
icon52-Week High24.34000
icon52-Week Low16.15000
iconAverage Volume2.92M
iconDividend Yield--
iconP/E Ratio37.9484
What does the Exelixis Inc do?
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Read More
How much money does Exelixis Inc make?
News & Events about Exelixis Inc.
TipRanks Financial Blog
8 months ago
Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Exelixis (EXEL Research Report) yesterday and set a price target of ... Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Exelixis (EXEL Re...
Zolmax
8 months ago
Deutsche Bank AG grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL Get Rating) by 3.7% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,550,060 shares of the biotechnology companys stock after purchasing an additional 91,086 shares during the period. ...
Business Wire
10 months ago
Funds managed by Farallon Capital Management, L.L.C. (Farallon) own approximately 7.2% of the outstanding shares of Exelixis, Inc. (NASDAQ: EXEL) (Exelixis or the Company), making it the Companys largest active shareholder. Today, Farallon filed definitive proxy materials in connection with...
TipRanks Financial Blog
10 months ago
In a report released yesterday, Chris Shibutani from Goldman Sachs maintained a Sell rating on Exelixis (EXEL Research Report). The companys sha... In a report released yesterday, Chris Shibutani from Goldman Sachs maintained a Sell rating on Exelixis (EXEL &#8211...
Zolmax
11 months ago
StockNews.com upgraded shares of Exelixis (NASDAQ:EXEL Get Rating) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. EXEL has been the topic of several other research reports. EF Hutton Acquisition Co. I reaffirmed a buy rating and issued a $24.00 price ...
Frequently Asked Questions
Frequently Asked Questions
What is Exelixis Inc share price today?
plus_minus_icon
Can Indians buy Exelixis Inc shares?
plus_minus_icon
How can I buy Exelixis Inc shares from India?
plus_minus_icon
Can Fractional shares of Exelixis Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Exelixis Inc stocks?
plus_minus_icon
What is today’s traded volume of Exelixis Inc?
plus_minus_icon
What is today’s market capitalisation of Exelixis Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Exelixis Inc?
plus_minus_icon
What percentage is Exelixis Inc down from its 52-Week High?
plus_minus_icon
What percentage is Exelixis Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$22.56
$0.32
(1.44%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00